Spots Global Cancer Trial Database for buparlisib
Every month we try and update this database with for buparlisib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium | NCT01551030 | Metastatic Tran... | Buparlisib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma | NCT01870726 | c-MET Inhibitor... | INC280 Buparlisib | 18 Years - | Novartis | |
| Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme | NCT01934361 | Recurrent Gliob... | buparlisib carboplatin lomustine placebo | 18 Years - | Novartis | |
| Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors | NCT01971489 | Adult Solid Neo... Recurrent Non-S... Stage IIIA Non-... Stage IIIB Non-... Stage IV Non-Sm... | Buparlisib Cisplatin Gemcitabine Hyd... Laboratory Biom... Pharmacological... Questionnaire A... | 18 Years - | Roswell Park Cancer Institute | |
| Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme | NCT01934361 | Recurrent Gliob... | buparlisib carboplatin lomustine placebo | 18 Years - | Novartis | |
| Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER) | NCT02452294 | Malignant Melan... Metastases | Buparlisib | 18 Years - | University Hospital Tuebingen | |
| Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma | NCT02303041 | Carcinoma, Basa... Recurrent Skin ... Skin Neoplasms Basal Cell Nevu... | Buparlisib Sonidegib | 18 Years - | Stanford University | |
| A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma | NCT02756247 | Lymphoma Mantle Cell Lym... Follicular Lymp... Diffuse Large B... | Buparlisib Ibrutinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC | NCT04338399 | Head and Neck C... | Buparlisib & Pa... | 18 Years - | Adlai Nortye Biopharma Co., Ltd. | |
| Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy | NCT01852292 | Head and Neck S... | Buparlisib Buparlisib matc... Paclitaxel | 18 Years - | Novartis | |
| Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy | NCT01852292 | Head and Neck S... | Buparlisib Buparlisib matc... Paclitaxel | 18 Years - | Novartis | |
| Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia | NCT02340780 | Chronic Lymphoc... | Buparlisib | 18 Years - | Canadian Cancer Trials Group | |
| Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients | NCT01911325 | Squamous Non-sm... | Buparlisib Buparlisib matc... Docetaxel | 18 Years - | Novartis | |
| The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC | NCT04338399 | Head and Neck C... | Buparlisib & Pa... | 18 Years - | Adlai Nortye Biopharma Co., Ltd. | |
| BKM120 for Patients With PI3K-activated Tumors | NCT01833169 | PI3K Pathway Ac... | BKM120 | 18 Years - 100 Years | Novartis | |
| Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | NCT01719250 | Recurrent Adult... Recurrent Grade... Recurrent Mantl... Refractory Mant... Transformed Rec... | Buparlisib Laboratory Biom... Questionnaire A... | 18 Years - | Mayo Clinic | |
| Palliative Thoracic Radiotherapy Plus BKM120 | NCT02128724 | Carcinoma, Non-... | BKM120 | 18 Years - | University of Oxford | |
| Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients | NCT01911325 | Squamous Non-sm... | Buparlisib Buparlisib matc... Docetaxel | 18 Years - | Novartis | |
| Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors | NCT01971489 | Adult Solid Neo... Recurrent Non-S... Stage IIIA Non-... Stage IIIB Non-... Stage IV Non-Sm... | Buparlisib Cisplatin Gemcitabine Hyd... Laboratory Biom... Pharmacological... Questionnaire A... | 18 Years - | Roswell Park Cancer Institute | |
| Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer | NCT01820325 | Non-Small Cell ... | Buparlisib Buparlisib plac... Carboplatin Paclitaxel | 18 Years - | Novartis | |
| Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia | NCT02340780 | Chronic Lymphoc... | Buparlisib | 18 Years - | Canadian Cancer Trials Group | |
| Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer | NCT01820325 | Non-Small Cell ... | Buparlisib Buparlisib plac... Carboplatin Paclitaxel | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
